[The use of diflucan in myelotoxic agranulocytosis].
Kliasova
G A
GA
D000208:Acute Disease; D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001853:Bone Marrow / Q000187:drug effects*; D002177:Candidiasis / Q000188:drug therapy* / Q000209:etiology; D003520:Cyclophosphamide / Q000009:adverse effects; D003561:Cytarabine / Q000009:adverse effects; D003630:Daunorubicin / Q000009:adverse effects; D004341:Drug Evaluation; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use*; D006801:Humans; D007938:Leukemia / Q000150:complications / Q000188:drug therapy; D011239:Prednisolone / Q000009:adverse effects; D014750:Vincristine / Q000009:adverse effects
D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D015725:Fluconazole; D011239:Prednisolone; D003630:Daunorubicin
Primenenie difliukana pri mielotoksicheskom agranulotsitoze.